We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.42B
AUM Growth
+$89M
Cap. Flow
+$262M
Cap. Flow %
10.81%
Top 10 Hldgs %
65.82%
Holding
53
New
8
Increased
8
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$181M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$147M
3
BABA icon
Alibaba
BABA
+$52.8M
4
LVTX
LAVA Therapeutics
LVTX
+$45.7M
5
LEGN icon
Legend Biotech
LEGN
+$6.93M

Top Sells

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$104M
2
INGN icon
Inogen
INGN
+$39.4M
3
VRNA
Verona Pharma
VRNA
+$14.7M
4
INZY
Inozyme Pharma
INZY
+$13.2M
5
HRMY icon
Harmony Biosciences
HRMY
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 65.06%
2 Financials 5.64%
3 Technology 5.23%
4 Communication Services 3.57%
5 Consumer Discretionary 2.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FSTX
51
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$377K 0.02%
34,819
– –
CRVS icon
52
Corvus Pharmaceuticals
CRVS
$1.17B
– –
-847,906
Closed -$3.02M
CTLT
53
DELISTED
CATALENT, INC.
CTLT
– –
-997,349
Closed -$104M
1 2
3

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q1 2021 Portfolio in Review

As of Q1 2021, Novo Holdings A/S held 53 positions worth $2.42B, up 3.8% from $2.33B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Novo Holdings A/S deployed $262M of net new capital in Q1 2021, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Edgewise Therapeutics: 5,587,207 shares worth $182M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 66% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Inogen, an estimated $39.4M trimmed.

  • Novo Holdings A/S's largest Q1 2021 buy was Edgewise Therapeutics: 5,587,207 shares worth $182M.
  • Novo Holdings A/S added most to Amicus Therapeutics in Q1 2021, an estimated $4.3M increase.
  • Novo Holdings A/S's biggest Q1 2021 reduction was Inogen, cutting an estimated $39.4M.
  • Novo Holdings A/S fully exited CATALENT, INC. in Q1 2021, selling an estimated $104M.
  • Novo Holdings A/S's ten largest holdings make up 66% of its $2.42B portfolio in Q1 2021.
  • Novo Holdings A/S opened 8 new positions and closed 2 in Q1 2021.
  • Novo Holdings A/S's portfolio value rose 3.8% quarter-over-quarter to $2.42B.

Based on Novo Holdings A/S's 13F filing for Q1 2021, filed 17 May 2021.